Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sox9 mRNA-LNP
- Development stage
- Preclinical
- Lead developer
- Kyungpook National University
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
Sox9 mRNA-LNP is an investigational lipid nanoparticle (LNP) formulation encapsulating messenger RNA (mRNA) that encodes SRY-box transcription factor 9 (SOX9), a master transcription factor essential for chondrogenesis and cartilage homeostasis. Developed by researchers at institutions including Kyungpook National University, National Taiwan University, and Peking Union Medical College Hospital, Sox9 mRNA-LNP is being evaluated for the treatment of osteoarthritis (OA) and cartilage regeneration. By delivering Sox9 mRNA directly into the joint via intra-articular injection, the therapy aims to restore chondrocyte homeostasis, promote extracellular matrix (ECM) synthesis (such as type II collagen and aggrecan), and suppress pathological Wnt signaling and catabolic enzymes like MMP13. Preclinical studies in rat models of osteoarthritis have demonstrated that intra-articular administration of Sox9 mRNA-LNP significantly attenuates pain behavior and preserves articular cartilage structure.
- Other names
- SOX9 mRNA-LNPSOX-9 mRNA-LNPSOX 9 mRNA-LNPSOX9 mRNA-LNPsSOX-9 mRNA-LNPsSOX 9 mRNA-LNPsSOX9@LNPSox9 mRNA-lipid nanoparticlesSox-9 mRNA-lipid nanoparticlesSox 9 mRNA-lipid nanoparticles
Beyond the preview
Go deeper on Sox9 mRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sox9 mRNA-LNP.